Synteract focusing on specific therapeutic areas as it eyes market growth

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/showcake)
(Image: iStock/showcake)
The contract research organization (CRO) Synteract today announced the creation of “therapeutic centers of development” as it looks to deepen its footprint in the mid-size CRO market space.

According to the company, the centers of development will include oncology – especially immunotherapy studies – pediatrics, neuro-degenerative disorders, as well as rare and orphan diseases.

"Our centers of therapeutic development are areas of specific focus where we have a lot of experience,"​ Synteract CEO Steve Powell told us. 

The CRO will continue to support other therapeutic areas where clients have needs, he explained; "However, by more clearly defining our areas of ​specialization we have an opportunity to make it easier to answer 'Why Synteract?'"

Echoing this sentiment in the press release, chief commercial officer Jack Shannon said that by “more clearly delineating”​ the company’s attention on “these growing development areas”​ it will have “a real opportunity”​ to expand its presence in the mid-market space​.

The new position was created in collaboration with its customers and internal teams, according to the company. 

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us

Products

View more

Webinars